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kit (Qiagen, Germany) followed by real-time polymerase chain reaction (PCR) using 1X TaqMan Universal master mix II (Applied Biosystems, USA), 500 nM of each primer (Forward = 5'CCATCCGATTATGC CACCTTTACAG3'; Reverse = 5'TCGAACGTTA GAGCGCACAA3) and 250 nM of NED labelled probe (5'TTGGAGGAAAACGTCTTTTTT3') targeting ORF 28 (DNA polymerase) and run on ABI 7500 real-time instrument.(Applied Biosystems, USA).
The Spearman's correlation coefficient (rs) and Mann-Whitney U-tests were performed. The P < 0.05 was considered statistically significant The SPSS version 22.0 (IBM, USA) was used for the statistical calculation.
results
In the present outbreak, 28 suspected cases of chickenpox were identified with median age of 8 years (1.5-38 years) and male-to-female ratio of 0.55:1. The cases occurred from the 3 rd week of May and lasted till the 2 nd week of August 2014. The children with age <15 years were mainly affected (64.3%). Two pregnant women were also infected, with a gestation period of 32 weeks and 28 weeks, respectively. The cases mainly presented with maculopapulovesicular lesions (96.43%) and fever (82.14%). None of the patients had received acyclovir treatment.
Out of 26 blood samples collected, 18 (69.23%) were found to have VZV IgM antibodies. Similarly, 18 (69.23%) patients were positive for VZV IgG antibodies. Both VZV IgM and IgG antibodies were detected in 14/26 (53.87%) patients. One out of 27 healthy controls was positive for VZV IgM antibodies, whereas 13/27 (48.15%) had IgG antibodies to varicella.
The VZV DNA could be demonstrated by real-time PCR in all the 8 vesicular swabs and 8 serum samples with mean viral load of 61,500 copies/µl (93.3-4.9 × 10 5 copies/µl) and 40,000 copies/µl (17.9-1.7 × 10 6 copies/µl), respectively [ Table 1 ]. A statistically significant positive correlation was found between viral load of vesicular swabs and serum samples r s = 0.88; P = 0.004. Out of 8 patients with active disease, 2 had mild infection and 6 had moderate/severe illness. A significant difference was found in viral load (serum and vesicular swabs) of patients with moderate/severe illness (median = 90500 copies/µl and 1, 95,500 copies/µl) compared to patients with mild presentation (median = 30 copies/µl and 354 copies/µl) (P = 0.046) [ Figure 1 ].
dIscussIon
This study reports the investigation of an outbreak of varicella in Burail which is inhabited by population from neighbouring states of Chandigarh who have low socioeconomic status and is overcrowded. As observed earlier, [7, 8] children <15 years of age were predominantly affected. Out of 28 cases, 20 were laboratory confirmed (18 confirmed by IgM testing and 2 additional samples positive by real-time PCR). Among 26 blood samples tested, 8 were found to be negative for anti-VZV IgM antibodies. Out of these 8 patients, 4 gave a history of previous varicella exposure and were positive for VZV IgG antibodies. Four patients did not have both anti-VZV IgM and IgG antibodies and gave a history of rash duration <5 days by which time the IgM antibody response may not have developed.
The detection and quantification of viremia during varicella infection may be potentially useful for diagnostic, prognostic and therapeutic monitoring purposes. [10] In our study, real-time PCR could detect viremia in patients presenting as early as 3 days of illness. An early diagnosis in an outbreak situation is desirable for prompt initiation of control measures, to prevent the further spread of outbreak, especially to pregnant women and immunocompromised individuals.
Varicella diagnosis and management in pregnancy demands little more attention based on the mortality rates. [11] Two pregnant women gave history of exposure to varicella cases, out of which one was detected to have fetal anencephaly during her level-II ultrasound at 18-20 weeks of gestation; however, she did not terminate her pregnancy and later acquired VZV infection. This patient had a high viral load in both serum and vesicular swab samples. She did not take any acyclovir treatment, and on follow-up, she had intrauterine fetal death. In contrast, the other pregnant lady who presented in convalescent phase received acyclovir treatment and delivered a healthy term baby.
The quantitative viral load detection has also been found useful in monitoring the treatment response of patients receiving antiviral therapy against VZV. [12] A limitation of our study was that the sample size of active cases was small to definitely comment on the correlation of viral load with disease severity. A positive correlation between viral load of vesicular swabs and serum samples suggests that vesicular swab samples can be used as an alternative to serum samples for viral load determination which is a less invasive procedure.
Majority (69.2%) of the cases identified in our study were primary cases of varicella as shown by the presence of VZM IgM antibodies. However, 4 patients had only anti-VZM IgG antibodies and were negative for anti-VZM IgM antibodies possibly suggesting reinfection. A limitation of our study was that the patients were not followed up as the basic aim of this study was to assess the role of real-time PCR in early diagnosis of varicella.
The introduction of varicella vaccine in the United States (1995) has drastically reduced the number of varicella cases, and thereby decreasing hospital admissions (88%) and childhood mortality (74%-92%) (2002). [13] VZV vaccine can also be useful in outbreak settings if given within 3-5 days of exposure. [14] This vaccine is found to have a good safety profile and high effectiveness, especially in immunocompetent individuals. The available evidence also support the use of two-dose vaccine over single dose as the second dose of varicella vaccine appears to be highly effective (93%) in preventing disease of any severity. Furthermore, the individuals receiving two doses of vaccine develop breakthrough disease less often, and when breakthrough disease does occur it is generally milder when compared to that unvaccinated individuals. [3, 15] This vaccine is presently recommended by the Indian Academy of Paediatrics to be given as two doses. [16] However, it is still not a part of Universal Immunisation Programme of our country. This contributes to one of the major reasons for the repeated occurrence of outbreaks. Various concerns which have decreased the worldwide acceptance of this vaccine are fear of increase of Herpes zoster incidence, the fear of age shift of the disease towards older age groups, and the economic burden of universal vaccination implementation. [17] The vaccine is currently available in India as Okavax (Aventis Pasteur) and Varilrix (GlaxoSmithKline) with approximate price of 1200-1500 INR.
The authors recommend that this vaccine should be included in the national immunisation schedule to control these outbreaks and a sustained use can also pave the way to a world without varicella.
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